NCT00741858

Brief Summary

The study evaluates two materials used for duraplasty of the posterior cranial fossa in treatment of Chiari malformation. One material (DuraGen) is a non-suturable collagen matrix that is applied over the defect if brain coverings (dura); the other (DuraGuard) is made out of bovine pericardium and has to be sutured during application. The study compares these two materials used for duraplasty of patients undergoing Chiari surgery in a prospective randomized fashion to check the rate of surgical complications associated with each material, patient's outcomes, length of surgery and the hospital stay, etc.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
34

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Apr 2003

Longer than P75 for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2003

Completed
5.4 years until next milestone

First Submitted

Initial submission to the registry

August 25, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 26, 2008

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2009

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2010

Completed
5.3 years until next milestone

Results Posted

Study results publicly available

July 13, 2015

Completed
Last Updated

July 13, 2015

Status Verified

July 1, 2015

Enrollment Period

6.7 years

First QC Date

August 25, 2008

Results QC Date

June 15, 2015

Last Update Submit

July 8, 2015

Conditions

Keywords

Chiari malformation;Duraplasty;Posterior fossa decompression;Duragen;Duraguard

Outcome Measures

Primary Outcomes (1)

  • Physical Health Quality of Life

    Physical health quality of life (based on SF-36 results) (SF-36 includes 8 scores scaled 0-100; lower score indicating more disability)

    7 years

Study Arms (2)

DuraGen (sutureless)

EXPERIMENTAL

Duragen duraplasty - the Duragen patch is applied over the dural defect during Chiari decompression surgery. The Duragen represents sutureless technique of posterior fossa duraplasty. Rest of the treatment is as usual.

Procedure: Duragen duraplasty

DuraGuard (suturable)

ACTIVE COMPARATOR

Duraguard duraplasty - the Duraguard patch is applied over the dural defect during Chiari decompression surgery and sutured to the dural edge. This represents suturable technique that theoretically provides better (water-tight) dural closure.

Procedure: Duraguard duraplasty

Interventions

Posterior cranial fossa repair and enlargement with application of dural patch (Duragen)

Also known as: Duragen (Arm 1; active comparator)
DuraGen (sutureless)

Posterior cranial fossa repair and enlargement with application of dural patch (Duraguard)

Also known as: Duraguard (Arm 2; active comparator)
DuraGuard (suturable)

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Symptomatic Chiari malformation

You may not qualify if:

  • Presence of ventriculoperitoneal shunt
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Illinois Medical Center in Chicago

Chicago, Illinois, 60612, United States

Location

Related Links

MeSH Terms

Conditions

Arnold-Chiari Malformation

Interventions

Estradiol

Condition Hierarchy (Ancestors)

Neural Tube DefectsNervous System MalformationsNervous System DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Intervention Hierarchy (Ancestors)

EstrenesEstranesSteroidsFused-Ring CompoundsPolycyclic CompoundsEstradiol CongenersGonadal Steroid HormonesGonadal HormonesHormonesHormones, Hormone Substitutes, and Hormone Antagonists

Results Point of Contact

Title
k.v. slavin
Organization
university of illinois at chicago

Study Officials

  • Konstantin V Slavin, MD

    University of Illinois at Chicago

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor Neurologic Surgery

Study Record Dates

First Submitted

August 25, 2008

First Posted

August 26, 2008

Study Start

April 1, 2003

Primary Completion

December 1, 2009

Study Completion

April 1, 2010

Last Updated

July 13, 2015

Results First Posted

July 13, 2015

Record last verified: 2015-07

Locations